NasdaqGS:BDSI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has BioDelivery Sciences International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BDSI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: BDSI's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-4.3%

BDSI

0.1%

US Pharmaceuticals

2.8%

US Market


1 Year Return

-44.0%

BDSI

5.7%

US Pharmaceuticals

20.7%

US Market

Return vs Industry: BDSI underperformed the US Pharmaceuticals industry which returned 5.7% over the past year.

Return vs Market: BDSI underperformed the US Market which returned 20.7% over the past year.


Shareholder returns

BDSIIndustryMarket
7 Day-4.3%0.1%2.8%
30 Day21.3%6.4%12.3%
90 Day0.3%-1.9%6.4%
1 Year-44.0%-44.0%8.5%5.7%23.4%20.7%
3 Year38.9%38.9%23.9%14.8%47.2%37.4%
5 Year-32.5%-32.5%36.3%20.6%94.1%72.7%

Long-Term Price Volatility Vs. Market

How volatile is BioDelivery Sciences International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioDelivery Sciences International undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BDSI ($3.82) is trading below our estimate of fair value ($52.15)

Significantly Below Fair Value: BDSI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BDSI is poor value based on its PE Ratio (24.9x) compared to the US Pharmaceuticals industry average (22.6x).

PE vs Market: BDSI is poor value based on its PE Ratio (24.9x) compared to the US market (19.7x).


Price to Earnings Growth Ratio

PEG Ratio: BDSI is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: BDSI is overvalued based on its PB Ratio (4x) compared to the US Pharmaceuticals industry average (3.6x).


Next Steps

Future Growth

How is BioDelivery Sciences International forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

44.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BDSI's forecast earnings growth (44.2% per year) is above the savings rate (2.2%).

Earnings vs Market: BDSI's earnings (44.2% per year) are forecast to grow faster than the US market (22% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BDSI's revenue (20.7% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: BDSI's revenue (20.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BDSI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioDelivery Sciences International performed over the past 5 years?

24.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BDSI has a large one-off gain of $5.0M impacting its September 30 2020 financial results.

Growing Profit Margin: BDSI became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: BDSI has become profitable over the past 5 years, growing earnings by 24.7% per year.

Accelerating Growth: BDSI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BDSI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: BDSI's Return on Equity (15.5%) is considered low.


Next Steps

Financial Health

How is BioDelivery Sciences International's financial position?


Financial Position Analysis

Short Term Liabilities: BDSI's short term assets ($168.6M) exceed its short term liabilities ($53.4M).

Long Term Liabilities: BDSI's short term assets ($168.6M) exceed its long term liabilities ($78.7M).


Debt to Equity History and Analysis

Debt Level: BDSI's debt to equity ratio (81.7%) is considered high.

Reducing Debt: BDSI's debt to equity ratio has reduced from 148.6% to 81.7% over the past 5 years.

Debt Coverage: BDSI's debt is well covered by operating cash flow (39.4%).

Interest Coverage: BDSI's interest payments on its debt are not well covered by EBIT (1.5x coverage).


Balance Sheet


Next Steps

Dividend

What is BioDelivery Sciences International current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BDSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BDSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BDSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BDSI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BDSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Jeff Bailey (57 yo)

0.50

Tenure

Mr. Jeffrey Allen Bailey, also known as Jeff, has been Chief Executive Officer at BioDelivery Sciences International, Inc. since November 4, 2020. Mr. Bailey served as Interim Chief Executive Officer at Bi...


Leadership Team

NamePositionTenureCompensationOwnership
Scott Plesha
President & Chief Commercial Officer2.83yrsUS$1.50m0.23%
$ 870.5k
Mary Coelho
CFO & Treasurer1.83yrsUS$1.12m0.012%
$ 44.7k
James Vollins
General Counsel2yrsUS$728.76kno data
Thomas Smith
Chief Medical Officer2.33yrsUS$1.01m0.0047%
$ 17.6k
Jeffrey Bailey
CEO & Director0.50yrno data0.045%
$ 169.5k
Joseph Lockhart
Senior Vice President of Operations2.83yrsno datano data
Kevin Ostrander
Senior Vice President of Business Development0.83yrno datano data
Bill McCarberg
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Boardno datano datano data
Arthur Lipman
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Boardno datano datano data
Jeff Katz
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Boardno datano datano data
Celeste Lindley
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Boardno datano datano data

2.0yrs

Average Tenure

57yo

Average Age

Experienced Management: BDSI's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Bailey
CEO & Director0.50yrno data0.045%
$ 169.5k
Bill McCarberg
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Boardno datano datano data
Arthur Lipman
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Boardno datano datano data
Jeff Katz
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Boardno datano datano data
Celeste Lindley
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Boardno datano datano data
Todd Davis
Independent Director2.5yrsUS$75.00k0.22%
$ 810.6k
Mark Sirgo
Vice Chairman4.08yrsUS$320.13k1.08%
$ 4.1m
Leo Whiteside
Member of Scientific Advisory Boardno datano datano data
David Perlin
Member of Scientific Advisory Boardno datano datano data
Peter Greenleaf
Independent Chairman2.5yrsUS$72.50k0.059%
$ 222.4k
Kevin Kotler
Independent Director2.5yrsUS$62.50kno data
William Watson
Independent Director2.92yrsUS$70.00k0.052%
$ 197.1k

2.5yrs

Average Tenure

58yo

Average Age

Experienced Board: BDSI's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.


Top Shareholders

Company Information

BioDelivery Sciences International, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioDelivery Sciences International, Inc.
  • Ticker: BDSI
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$376.133m
  • Shares outstanding: 101.11m
  • Website: https://www.bdsi.com

Number of Employees


Location

  • BioDelivery Sciences International, Inc.
  • 4131 ParkLake Avenue
  • Suite 225
  • Raleigh
  • North Carolina
  • 27612
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BDSINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2002
BD5DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2002

Biography

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The compa...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 23:55
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.